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Abstract
Sodium phosphate nephropathy consists of damage to the kidneys caused by the use of laxatives containing 
sodium phosphate.  Depending on the time of use of these drugs used for colonic preparation this disease can 
be acute or chronic. The acute condition can be cured with a suitable treatment, but the chronic condition can 
cause irreversible kidney damage.
This case is about a patient who receives our services in the unit in Fundación Cardio Infantil in Bogotá, 
Colombia, with an acute kidney injurywith renal transplant being monitored. Sodium phosphate was used to 
be prepared the kidney for a colonoscopy.
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Nefropatía por agente catártico basado en fosfato de sodio en paciente renal 
trasplantado. Reporte de un caso
Resumen
La nefropatía por fosfato de sodio es una forma de lesión renal que ocurre posterior al uso de laxantes que 
contienen fosfato de sodio. Puede presentarse de manera aguda o crónica según el tiempo de utilización de 
dichos medicamentos utilizados para la preparación colónica. La forma aguda puede resolverse con un ade-
cuado tratamiento, pero la forma crónica puede causar daño renal irreversible.
Este caso se trata de una paciente con trasplante renal, en seguimiento en la Fundación Cardioinfantil en 
Bogotá, Colombia, en quien se utilizó fosfato de sodio para una preparación de colonoscopia y se presentó a 
nuestro servicio con una lesión renal aguda.
Palabras clave: Enfermedad renal crónica, nefropatía por fosfato de sodio, diagnóstico (fuente DeCS).
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40 years female patient, who was attended for a kidney transplant consult and monitoring, with acute flushedrise. To study her acute kidney 
injury during renal transplant, she was hospitalized.
During hospitalization, she reported diarrhea(more 
than 3 times per day) for nearly 5 months of progres-
sion  without emesis or abdominal pain. Through a 
colonoscopy this symptomatic state was studied for 
two weeks. The bowel preparation was performed 
with phosphate enema. The rest of the review by the 
system was negative.
Based on pathological antecedents, the patient had 
arterial hypertension, because of urinary tract in-
fection to repetition, deep vein thrombosis 10 years 
prior, pulmonary thrombo embolism, 10 years prior, 
and systemic lupus erythematous that produced 
chronic kidney disease that required renal replace-
ment therapy, initially treatment with hemo-dialysis 
and  5 years before, and renal transplantation. The 
immune suppression consisted of tacrolimus XL 4 
mg/day, mycophenolatemofetil of 720 mg/d, ome-
prazole 20 mg/day, Deflazacort 6 mg/day, Enalapril 
20 mg/day. 
There were no alterations in their physical examina-
tion, patientvital signs eranTA: 139/76,FC: 72/m, Fr: 
16/m. The paraclinical are summarized in Table 1:
Outpatient Colonoscopy: study within normal limits. 
Urine - analysis: density: 1010,Ph: 5.5, proteins: 
negative; sediment=leukocytes: 3.96, erythro-
cytes:1.78, bacteria:+.
Anti DNA: negative Snap-in: Normal.
Levels of tacrolimus: 5.39.
Echo Doppler of transplanted kidney: normal.
Stool=Ph: 8, hidden blood: negative, not observed 
parasites. ZN modified  stool: negative for Cryptos-
poridium, cyclospora and microsporidium. 
HIV: negative.
It was decided to perform renal biopsy, which 
showed existence of tubular acute damage with 
changes of regeneration, presence of calcium phos-
phate crystals and distribution in bands. Tubular 
damaged is caused by the presence of interstitial 
nephritis moderate with tubular mild. Without evi-
dence of polyoma virus nephropathy or nephropathy 
immune complexes. 
In this particular case,consisten tchanges  in acute 
cellular rejection are identified by the presence of 
insufficient quantities of tubular-intestinal inflam-
matory infiltrates, associated with the presence of 
tubular-highlights and the presence of two types of 
crystals:1)Calcium, whose presence indicates two 
types of tubular damages. The first of them, calcium 
oxalates, characterized by the presence of yellowish 
crystals,  Hematoxylin coloration appearance and 
Eosin, which protrude when exposed to the polari-
zed light; and 2) crystals derived from renal tubular 
damage. Its presence was indicated but resolved be-
cause of the status of tubular scarring due to cathar-
sis by enema of sodium phosphate.
The presence of nephropathy by crystals of phos-
phate was handled by administering postprandial 
aluminum, calcium carbonate postprandial and a 
short course of steroids was conducted. With this 
treatment, the patient showed the improvement of 
kidney function to base values.
Comments
For colon cleaning and preparation several agents 
were used.  One of the most frequently used is a so-
dium phosphate based enema which was introduced 
therapeutically for first time by Vannery collabora-
tors in 19901.
Sodium phosphate enemas function as osmotic laxa-
tive preparations, i.e. by its high osmolarity to “for-
Table 1
Azoados variation
 Serum  Blood urea 
 creatinine (mg/dL)  nitrogen  
  (mg/dL)
Basal Values  1,2 22
At the time of the 1,8 43 
present disease
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Figura 2
Imágenes de una porción de la biopsia sin (C, E) y con exposición a luz polarizada (D, F). Nótese 
la presencia de los cristales birrefringentes indicativos de la presencia de cristales de oxalatos 
(Hematoxilina y Eosina 10X)
Figura 1
A. Imagen correspondiente a panorámica de la biopsia renal. Nótese la presencia de corteza renal con algu-
nos grupos inflamatorios (Hematoxilina y Eosina a 4X)
B. Imagen correspondiente a panorámica de la biopsia renal, otras áreas con carácterísticas similares a las 
vistas en A. (Hematoxilina y Eosina a 4X)
A.  B.
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ce” water excretion in the intestinal lumen, giving 
as a result  an increase of the peristalsis and bowel 
movement2. The usual dose of sodium phosphate is 
two doses between 8 and 12 hourintervals3. Forty-fi-
ve milliliters of sodium phosphate contain5 grams 
of sodium and 17 grams of phosphate (equivalent 
to 11.5 g of elemental phosphorus). That dosage can 
cause a loss of up to 1.6 lde intestinal fluid. This loss 
of volume, together with the oral ingestion,  dictated 
by pre-colonoscopy protocols, can produce altera-
tions of the electrolytes and increases the risk of kid-
ney damage in patients receiving these agents (4).
For first time in 2003, an unusual form of nephro 
calcinosis cortical due to “acute nephropathy by 
phosphate” was described.  Since then, several re-
ports have been associated with renal insult, both 
acute and chronic2,3.Since its discovery, 37 cases 
(between 2003 and 2010) approximately,  have 
been documented. A majority of the cases were de-
rived from centers of study in the USA, others from 
Norway, Netherlands, Belgium, United Kingdom, 
Lebanon, Korea, New Zealand and five fromIsrael. 
This reference reflects that sodium phosphate5 is on 
the widespread.
Dr. Ehrenpreis and collaborators’ retrospective 
study, was based on the data of adverse events from 
the Food and Drug Administration(FDA),from2004 
to 2009. The data showed that in women with an 
average weight lower than normal (68.57 ± 1.78 kg) 
6, the tablet of sodium phosphate consumption is as-
sociated with renal lesions.
In Brazil, one in every thousand doses sold of so-
dium phosphate develops acute nephropathy by 
phosphate. The relationship between the sodium 
ingestion and the calcium and phosphate reservoir 
are related with renal lesion with an interstitial and 
concomitant renal function loss. 
Additionally, the sodium phosphate enema prepa-
ration causes increases in serum phosphorus, even 
among patients with normal renal function. Phos-
phorus levels with normal renal function ranged be-
tween 3.7 to 7.3 mg/dL, after administering sodium 
phosphate7. Another study found levels of phos-
phorus above 8 mg/dl in 28% of patients treated with 
sodium phosphate8.
On the other hand, some studies report a significant 
trend toward better results in renal outcomes after 
the use of sodium phosphate, compared with other 
laxatives9-11. A study in an Asian population did 
not demonstrate alterations in renal function during 
12 to 24 months of monitoring, after using sodium 
phosphate for colonic preparation5.
The acute phosphate nephropathy (APN,by its 
acronym in English) occurs after the use of these co-
lon agents preparation, and it has two forms of pre-
sentation: acute kidney injury (AKI) and the chronic 
renal disease  (CRD)3. 
AR presentation might occur in hours or days; it is 
accompanied by Hypocalcemia and normally  it is of 
short duration. It can be treated with chelating agents 
of phosphorus conservative therapy that often lead 
to a total renal recovery 12. The acute Hypocalcemia 
is almost characteristic of this entity and is secon-
dary to calcium and phosphorus precipitation, which 
could be further exacerbated if the patient presents 
an acute respiratory alkalosis, which could lead to 
the tetany manifestation 1.
The chronic form of APN may occur weeks after 
the initial exposure, which hinders its identification, 
Figura 3
Presencia de cristales de fosfatos de calcio en las 
luces tubulares, evidentes como concreciones 
basófilas (flechas)  irregulares, las cuales no 
polarizan al exponerlas a la luz polarizada. 
También se aprecian bandas de fibrosis intersticial 
asociadas a atrofia tubular. 
Rev. Colomb. Nefrol. 2016; 3(1): 49 - 54
Pineda R, Molano A, Flórez A, D`Achiardi R, Wancjer B 53
being almost always diagnosis based on a judicious 
and interrogation in renal biopsy, since its symptoms 
are unspecific and easily explainable by the deterio-
ration of renal function. Renal biopsy in patients 
with CKD due to APN, usually show nephrocalcino-
sis.  Nephrocalcinosis is a tubular-interstitial disea-
se, with prominent tubular calcification with tubular 
atrophy and interstitial fibrosis. There is tubular in-
jury, secondary to the deposit of crystals of calcium 
and phosphorus and the increase of the phosphate 
concentration intertubular and  hyperphosphatemia. 
Most of the calcium phosphate precipitations are 
found in distal and main fold tubules. 
An increase in the re-absorption of sodium and wa-
ter in the  proximal tubule (which is impervious to 
the phosphorus) and the re-absorption of water wi-
thout phosphorus re-absorption in the loop of Henle 
is led by the volume depletion that accompanies the 
use of these osmotic laxatives agents, exacerbating 
this process, which results in a higher relative con-
centration of calcium and phosphorus in the distal 
tubule13. The deposit of calcium phosphate crystals 
in the distal renal tubule can only be confirmed by 
a biopsy, because the inter-renal tank, in hyperphos-
phatemia acute, is not usually detectable in the ra-
diological images2,4,14,15.
The presentation of APN is potential, at the time a 
patient with renal dysfunction is exposed to high do-
ses of phosphate. 
In addition to the potential risk of APN, the prepara-
tions of sodium phosphate enema include transient 
hypocalcemia and hypopotassemia in more than 
50% ofthe elderly,16 even with normal renal func-
tion. The hyperkalemia and hypokalemia that occur 
after its use, it might affect the cardiac rhythm, pro-
longing the QT interval and producing ventricular 
arrhythmias, as well as macroscopic and histological 
changes in the mucosa, so use must be avoided in 
those with inflammatory bowel disease17.
The risk factors for nephropathy by sodium phos-
phate are: ERC, females greater than 55 years, and 
medications to decrease the intravascular volume 
and renal perfusion (e.g. antagonistic diuretics, an-
giotensin receptor -converting enzyme inhibitors, 
non-steroidal anti-inflammatory drugs, etc.), the fre-
quency of the medication dose (every 6 hours vs. 
every 12 hours increases the levels of phosphorus) 
and its use should be avoided  in intestinal obstruc-
tion and active colitis18.
The way to prevent the disease19:
1. Avoid use in high-risk patients.
2. Use the minimum effective dose, the total 
amount of phosphate which is excreted in the 
urine after the second dose is from three to four 
times greater than that eliminated after the first 
dose; this suggests that the second dose is par-
ticularly dangerous, so that a reduction or re-
placement with another agent (p.e.polyethylene 
glycol) is indicated.
3. Increasing the interval between doses; an inter-
val of 24 h reduces the incidence of hyperphos-
phatemia, which is considered clinically impor-
tant, without loss of effectiveness in comparison 
with a range of 9-12 h.
4. Avoid dehydration; abundant liquid should be 
administered orally or intravenously.
5. Perform biochemical tests before the colonos-
copy and measure the renal function and elec-
trolytes; mainly in patients with high risk or uns-
table.
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